Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis
- 174 Downloads
Gestational diabetes mellitus (GDM) is a medical complication of any degree of glucose intolerance with onset or first recognition during pregnancy. Although visfatin is commonly considered to be related to GDM, studies revealed inconsistent results. This study aimed to clarify the relationship between visfatin and GDM.
The protocol for this study was registered in PROSPERO (No. CRD42018086204) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed and Embase databases were used to search for relevant studies published up to September 30, 2017. The difference of visfatin levels between women with GDM and the controls was measured by standardised mean difference (SMD) and 95% confidence interval (CI).
Twenty-six studies that were published in 24 articles met the inclusion criteria, in which 2305 participants (1033 with GDM, mean age 31.39 years and 1272 controls, and mean age 29.99 years) were included. The quantitative meta-analysis revealed no significant difference in circulating visfatin levels between women with GDM and the controls (SMD = 0.249, 95% CI = − 0.079 to 0.576, P = 0.137). Subgroup analyses were performed referring to body mass index (BMI) where inconsistent results have been observed between cases and controls groups. For the ten studies, in which the level of BMI in women with GDM was higher than that in the control group, the pooled result showed that circulating visfatin was significantly higher among women with GDM than the controls (SMD = 0.367, 95% CI = 0.06 to 0.728, P = 0.046). Of other 16 studies BMI-matched, the pooled SMD illustrated no difference of visfatin.
Our study elucidates that visfatin is not independently associated with GDM. Visfatin is linked to GDM through maternal overweight/obesity, which is one of the major factors leading to the development of GDM.
KeywordsGestational diabetes mellitus Visfatin Body mass index
We would like to thank Wei Wang, Edith Cowan University School of Medical and Health Sciences, for his help with conducting a scoping review for this study.
HH, AD, and XJ designed the study. WZ, DZ, ZM HW, KZ, XF, and YL conducted the literature search, performed data extraction, and assessed study quality. HH and XJ conducted the statistical analyses. HH and AD wrote the manuscript. All authors interpreted data and revised the manuscript for important intellectual content. HH conceived of the study idea, supervised the study, and is the guarantor.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
This study used published, aggregate data and did not involve human participants or animals. Consequently, research ethics board review was not required.
- 1.Daly B, Toulis KA, Thomas N et al (2018) Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: a population-based cohort study. PLoS Med 15(1):e1002488CrossRefGoogle Scholar
- 21.Hossein-nezhad A, Mirzaei K, Maghbooli Z, Rahmani M, Larijani B (2010) Resistin, adiponectin and visfatin; can adipocytokines predict gestational diabetes mellitus and early post partum metabolic syndrome? Iran J Diabetes Lipid Disord 9:1–8Google Scholar
- 22.Lei C (2009) The analysis of serum adiponectin and visfatin levels in pregnancy with different glucose tolerance and the effect on the secretary function of beta cell. Dissertation. Ningxia Medical University, YinchuanGoogle Scholar
- 25.Boyadzhieva M, Atanasova I, Zacharieva S, Kedikova S (2013) Adipocytokines during pregnancy and postpartum in women with gestational diabetes and healthy controls. J Endocrinol Investig 36(11):944–949Google Scholar